Social prescribing could have a big impact on helping people stay healthy and lighten the burden on England’s overstretched NHS - but barriers remain to it being taken up more widely.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh